Cellgenes

Cellgenes (Guangzhou Cellgenes Biotechnology) is a clinical-stage biotechnology company based in Guangzhou, China, focused on the development and commercialization of advanced stem cell-based therapies. Founded in 2016, the company utilizes proprietary stem cell engineering and scalable expansion platforms to create treatments for regenerative medicine and emergency critical care. Its lead candidate, CG-BM1, is an allogeneic bone marrow-derived mesenchymal stem cell (MSC) injection currently in Phase 2 clinical trials for indications including ischemic stroke and acute-on-chronic liver failure. Cellgenes is also developing a pipeline of second-generation targeted MSCs and tissue-specific stem cell solutions to address organ-specific medical needs. In March 2026, the company raised over $14 million in Pre-C financing to advance its clinical programs and support its expansion into international markets.